ADIAL: The Phase 3 ONWARD™ trial meets its screening target and nears enrollment completion

July 6, 2021 Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) announced that the Company has made significant progress on its pivotal ONWARD Phase 3 clinical trial having met 100% of its patient screening target and having achieved 90% of its patient enrollment target. The ONWARD trial is evaluating AD04 as a therapeutic agent for the treatment […]

Read more

Promising results from clinical trial for the treatment of Celiac Disease

Dr. Falk Pharma GmbH and Zedira GmbH have announced successful completion of the phase 2a clinical trial of ZED1227, a direct-acting and specific inhibitor of tissue transglutaminase, in patients with celiac disease. The clinical trial demonstrated a substantial protective effect of the first-in-class drug candidate ZED1227 on the duodenal mucosa during a 6-week gluten challenge. […]

Read more